Non-invasive prenatal test to screen common trisomies in twin pregnancies

Non-invasive prenatal test to screen common trisomies in twin pregnancies
Mahtab Motevasselian1 , Soraya Saleh Gargari1*, Sarang Younesi2 , Parichehr Pooransari1 , Pourandokht Saadati2 , Masoomeh Mirzamoradi1 , Shahram Savad2 , Mohammad Mahdi Taheri Amin2 , Mohammad-Hossein Modarresi3 , Maryam Afrakhteh1 and Soudeh Ghafouri-Fard4*
Abstract
Objectives:
Recent years have witnessed a shift from invasive methods of prenatal screening to non-invasive strategies . Accordingly, non-invasive prenatal testing (NIPT) using cell-free fetal DNA in maternal plasma has gained a considerable deal of interest from both geneticists and obstetricians. Efficacy of this method in identification of common aneuploidies has been extensively assessed in singleton pregnancies. However, a limited number of studies have addressed the twin pregnancies. In this context, the present study is aimed at identification of the efficacy of NIPT in twin pregnancies.
Methods:
NIPT was performed on twin pregnancies to screen trisomies 13, 18 and 21. Pregnant women referring to Nilou Clinical Laboratory between March 2016 and December 2018 were included in this research
Results:
In the current study, a total 356 twin pregnancies were screened in search for trisomies 13, 18 and 21. 6 cases exhibited positive NIPT results in which the presence of trisomies 13, 18 and 21 was confirmed by fetal karyotype in 1, 2 and 2 cases, respectively. One twin pregnancy showed normal karyotype. The combined false-positive rate for these trisomies was 0.28%. No false negative case was observed. The combined sensitivity and specificity of NIPT in twin pregnancies were 100 and 99.7%, respectively.
Conclusion:
The results of the current study verify the feasibility, sensitivity and specificity of NIPT in twin pregnancies.
Keywords: NIPT, Non-invasive prenatal testing, Cell free DNA, Trisomy 21, Trisomy, 18, Trisomy 13, Twin pregnancy
-
Launch of the first FDA-approved technology in Iran to diagnose HPV (updated)
-
Errors in POCT (Point of Collection Testing) and alternative site testing
-
First-Trimester Contingent Screening for Trisomy 21 by Fetal Nuchal Translucency and Maternal Serum Biomarkers and Maternal Blood Cell-Free DNA Testing
-
Human papilloma virus (HPV) genotypes concordance between Iranian couples referrals
-
Some Points about Serum biochemistry in prenatal screening
-
Some points about the Nuchal Translucency in Ultrasound according to FMF
-
New Findings on the Use of Fibrinogen in Gynecological Diseases
-
Fine-tuning of routine combined first- trimester screening
-
The decision to discontinue home isolation should be made in the context of local circumstances.
-
Coronavirus and Laboratory Quality